Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Recommendation of "Buy" from Analysts

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) has been given an average recommendation of "Buy" by the six analysts that are covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $30.83.

A number of equities analysts recently issued reports on the stock. Wedbush reaffirmed an "outperform" rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Friday, March 28th. HC Wainwright restated a "buy" rating and issued a $30.00 price target on shares of Tyra Biosciences in a research report on Monday, March 31st.

Tyra Biosciences Price Performance

NASDAQ:TYRA traded up $0.34 during midday trading on Monday, reaching $10.20. The stock had a trading volume of 21,294 shares, compared to its average volume of 260,377. The firm's fifty day simple moving average is $9.57 and its 200-day simple moving average is $12.90. The stock has a market capitalization of $541.52 million, a P/E ratio of -6.32 and a beta of 1.17. Tyra Biosciences has a 1-year low of $6.42 and a 1-year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. On average, equities research analysts anticipate that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Alta Partners Management Company L.P. bought a new stake in shares of Tyra Biosciences in the 4th quarter valued at approximately $56,716,000. Boxer Capital Management LLC acquired a new position in shares of Tyra Biosciences during the fourth quarter valued at $28,185,000. Vestal Point Capital LP increased its position in Tyra Biosciences by 190.9% in the first quarter. Vestal Point Capital LP now owns 2,879,829 shares of the company's stock worth $26,782,000 after purchasing an additional 1,889,829 shares during the period. Farallon Capital Management LLC acquired a new stake in Tyra Biosciences in the fourth quarter worth about $13,914,000. Finally, Orbimed Advisors LLC raised its holdings in Tyra Biosciences by 91.3% during the 4th quarter. Orbimed Advisors LLC now owns 1,470,086 shares of the company's stock worth $20,434,000 after purchasing an additional 701,448 shares during the last quarter. 84.14% of the stock is owned by institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.